Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308005 | 0.99 | PPARG (0.57) | PPARGTP53TSHRPLA2G4BAGTR1 | |
| SCHEMBL6303646 | 0.99 | PPARG (0.57) | PPARGTP53TSHRPLA2G4BAGTR1 | |
| SCHEMBL6303584 | 0.99 | PPARG (0.56) | PPARGTP53TSHRPLA2G4BAGTR1 | |
| SCHEMBL6301097 | 0.95 | PPARG (0.52) | PPARGTSHRAGTR1AGTR2 | |
| SCHEMBL6308646 | 0.92 | PPARG (0.56) | PPARGTSHR | |
| SCHEMBL6301337 | 0.91 | PPARG (0.51) | PPARGTSHR | |
| SCHEMBL6304029 | 0.91 | PPARG (0.55) | PPARGTSHR | |
| SCHEMBL6307980 | 0.91 | PPARG (0.55) | PPARGTSHR | |
| SCHEMBL6303322 | 0.90 | PPARG (0.49) | PPARG | |
| SCHEMBL6487612 | 0.90 | PPARG (0.51) | PPARGTSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908729-B2 | Amplified photoresist; radiation with ultraviolet radiation | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-6869950-B1 | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-20030082486-A1 | Pattern formation method | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1142880-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885TP53 1741/4885TSHR 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.